Gossamer Bio, Inc. (NASDAQ:GOSS) Short Interest Update

Gossamer Bio, Inc. (NASDAQ:GOSS – Get Rating) was the recipient of a large increase in short interest in February. As of February 28th, there was short interest totalling 26,620,000 shares, an increase of 5.4% from the February 13th total of 25,250,000 shares. Approximately 35.6% of the shares of the company are sold short. Based on an average daily trading volume, of 5,970,000 shares, the short-interest ratio is currently 4.5 days.

Institutional Trading of Gossamer Bio

Large investors have recently added to or reduced their stakes in the company. Martingale Asset Management L P increased its stake in Gossamer Bio by 39.7% in the 2nd quarter. Martingale Asset Management L P now owns 50,027 shares of the company’s stock worth $420,000 after acquiring an additional 14,215 shares during the last quarter. Delphia USA Inc. bought a new stake in Gossamer Bio in the 2nd quarter worth approximately $100,000. Tudor Investment Corp Et Al bought a new stake in Gossamer Bio in the 3rd quarter worth approximately $561,000. Sequoia Financial Advisors LLC bought a new stake in Gossamer Bio in the 3rd quarter worth approximately $132,000. Finally, Cormorant Asset Management LP increased its stake in Gossamer Bio by 1,512.2% in the 3rd quarter. Cormorant Asset Management LP now owns 3,198,382 shares of the company’s stock worth $38,317,000 after acquiring an additional 3,000,000 shares during the last quarter. Institutional investors own 90.18% of the company’s stock.

Gossamer Bio Stock Performance

NASDAQ:GOSS opened at $0.96 on Friday. The company has a debt-to-equity ratio of 3.73, a current ratio of 5.93 and a quick ratio of 5.93. Gossamer Bio has a 1 year low of $0.96 and a 1 year high of $15.20. The stock’s 50 day simple moving average is $2.05 and its two-hundred day simple moving average is $6.70. The company has a market cap of $90.80 million, a price-to-earnings ratio of -0.33 and a beta of 1.25.

Analysts Set New Price Targets

GOSS has been the topic of a number of analyst reports. SVB Leerink lowered their price objective on Gossamer Bio from $15.00 to $10.00 and set an “outperform” rating on the stock in a research report on Wednesday, December 7th. UBS Group lowered their price objective on Gossamer Bio from $19.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, December 7th. Evercore ISI decreased their target price on Gossamer Bio to $7.00 in a research note on Monday, December 12th. Bank of America decreased their target price on Gossamer Bio from $15.00 to $7.00 in a research note on Wednesday, December 7th. Finally, The Goldman Sachs Group decreased their target price on Gossamer Bio from $22.00 to $10.00 and set a “buy” rating on the stock in a research note on Wednesday, December 7th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $9.42.

Gossamer Bio Company Profile

(Get Rating)

Gossamer Bio, Inc engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions.